Kornimate/medical-research-clean huggingface dataset:
pharmacist discharge medication reconciliation study

Conditions: Medication Reconciliation

Summary: adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission at the cci. the purpose of this study is to see if pharmacist medication reconciliation at discharge reduces unintentional medication discrepancies for inpatient discharges.


Eligibility criteria:
inclusion criteria: * cancer inpatients under the care of dr. follett or dr. candler * cancer inpatients to be discharged from the cci * patients \>18 years of age * patients that are taking \>1 medications or herbals total at home. exclusion criteria: * cancer inpatients that are considered radioactive or in "hot rooms" (ie. selectron patients or patients receiving radiation treatment for thyroid) * patients that do not remain in hospital \>72 hours * patients without a home phone number or equivalent contact number. * language barrier (patients unable to speak or understand english). * patients that are readmitted and already included into the study.

Keywords: cancer cancer mrs treatment response histologically confirmed diagnosed breast cancer. patient is 18 years or older. karnofsky performance score is equal to or greater than 70. no previously irradiated or recurrent breast. no contraindication to mrs/mri.
visualizations to improve pain communication between patients, interpreters, and providers

Conditions: Communication; Pain

Summary: the purpose of this study is to pilot test a pain assessment information visualization (infoviz) tool to facilitate communication about pain severity, location, and quality to increase mutual understanding between patients with limited english proficiency (lep), interpreters, and providers during pain assessment. 40 participants will be enrolled and can expect to be on study for up to 4 weeks.

the purpose of this study is to pilot test a pain assessment information visualization (infoviz) tool to facilitate communication about pain severity, location, and quality to increase mutual understanding between patients with limited english proficiency (lep), interpreters, and providers during pain assessment. the investigators focus on the lep hmong because pain is particularly problematic for this group. the hmong describe pain using visual metaphors that are inconsistent with providers' knowledge and interpreters struggle to translate metaphors accurately between patients and providers. the goals of the study are (1) to examine the feasibility of implementing the pain infoviz tool, (2) to explore congruency of patient-interpreter-provider triads' mutual understanding (mu) of pain severity, location, and quality, and (3) to evaluate outcome measures selected to capture satisfaction with communication, pain relief, and pain interference with life and explore variables identified in the infoviz tool conceptual framework (mu of pain assessment information, satisfaction with communication, pain diagnosis and treatment). the investigators will first collect data from 20 participants under the usual care control condition (i.e., interpreters verbally interpreting and communicating pain descriptions), followed by data collection from another 20 participants under the intervention condition (i.e., interpreters using verbal descriptions and the infoviz tool). the investigators believe that the pain assessment infoviz tool will increase mutual understanding of pain severity, location, and quality between patients, interpreters, and providers, and consequently lead to increased satisfaction with communication, greater pain relief and reduced pain interference with daily life through better-informed diagnosis and treatment.

Eligibility criteria:
inclusion criteria: * age 18 and up * hmong patients that indicate they do not speak english well (lep) * self reported pain exclusion criteria: * indicate that they speak english well interpreter inclusion criteria: * 13 years old or greater * self-identify as interpreting for a hmong individual in the health care setting interpreter exclusion criteria: * telephone interpreters as they are unable to view and use the infoviz tool

Keywords: pain assessment limited english proficiency mutual understanding
a phase ii study of paclitaxel, uft, and leucovorin in patients with metastatic esophageal cancer

Conditions: Esophageal Neoplasm

Summary: this study is for patients with esophageal cancer that has spread to other areas. the purpose of this study is to: 1. determine how well a combination of taxol, uft, and leucovorin work in these patients, 2. determine the survival of patients with metastatic esophageal carcinoma treated with this combination of drugs. 3. identify the side effects of this drug combination.


Eligibility criteria:
inclusion * histologic proof of esophageal cancer * no more than one prior non-taxane chemotherapy regimen for either treatment of localized disease or metastatic disease and they may not have received a regimen containing low dose continuous infusion of 5-fu (i.e. \>5 days of infusion/cycle), capecitabine or uft * no prior therapy with uft+/-leucovorin, a taxane, capecitabine, low dose continuous infusion of 5-fu or ethynyl uracil. * radiographic or physical examination documentation of metastatic disease * no major surgery within the 2 weeks preceding the start of treatment and fully recovered from any complications of surgery * no radiation within 2 weeks of beginning chemotherapy. * no chemotherapy within 4 weeks of beginning treatment. * patients must wait at least 6 weeks after receiving bcnu or mitomycin-c. * minimum life expectancy of 3 months * informed consent given * laboratory values within limits set by study. exclusion * more than one prior chemotherapy regimen for metastatic disease * current serious medical or psychiatric illness that would prevent informed consent or intensive treatment * \>grade 1 peripheral sensory or motor neuropathy * pregnant * patient is taking the drug sorivudine
effect of nsaid on travoprost-induced conjunctival hyperemia and iop reduction in normal eyes

Conditions: Hyperemia; Intraocular Pressure

Summary: pg-analogues induce hyperemia as one of side effects in addition to iop reduction. iop reduction is caused by direct fp receptor stimulation, but the cause of hyperemia is not clarified. because fp receptor stimulation induce intrinsic production of pgs, hyperemia or iop reduction may be due to secondary induced pgs. thus, pretreatment with nsaid may affect the pg-analogue induced hyperemia or iop reduction.


Eligibility criteria:
inclusion criteria: 1. normal healthy eye 2. not applicable for iop level 3. not wearing contact lenses 4. not applicable for the presence of the ocular surface diseases in case the treatment was not needed exclusion criteria: 1. the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection 2. the eyes with the history of trauma, intraocular surgery, or laser surgery within 6 months 3. the eyes with difficulty for the measurement of iop with the applanation tonometer 4. the subjects with the allergy for pg-analogues or benzalkonium chloride 5. the subjects using the eyedrops excluding those in this study 6. the subjects treated with oral carbonic anhydrase inhibitor 7. the subject with sjogren syndrome 8. the subjects who can not drop periodically 9. the subjects with the advanced glaucoma or the terminal stage of glaucoma 10. the subjects with the severe ocular complications
r115777 in treating patients with recurrent or metastatic non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of r115777 in treating patients who have recurrent or metastatic non-small cell lung cancer.

objectives: * assess the response rate of patients with recurrent or metastatic non-small cell lung cancer when treated with tipifarnib. * determine the clinical toxicities of this treatment in these patients. * assess the overall survival and time to progression of this patient population when treated with this regimen. * evaluate the inhibition of protein farnesylation in vivo and correlate such inhibition to plasma levels of tipifarnib. * evaluate the occurrence of cyp450 polymorphisms and relate these to drug toxicity, pharmacokinetics, and response to this treatment in this patient population. outline: this is a multicenter study. patients receive oral tipifarnib twice daily on days 1-21. treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for 5 years. projected accrual: a total of 50 patients will be accrued for this study over 12 months.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed recurrent or metastatic non-small cell lung cancer (nsclc) * measurable disease * at least 20 mm in at least one dimension * nonmeasurable is defined as any of the following: * bone lesions * leptomeningeal disease * ascites * pleural/pericardial effusion * inflammatory breast disease * lymphangitis cutis/pulmonis * abdominal masses not confirmed and followed by imaging techniques * cystic lesions * no cns metastases patient characteristics: age * 18 and over performance status * ecog 0-2 life expectancy * at least 12 weeks hematopoietic * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic * bilirubin no greater than 2 times upper limit of normal (uln) * ast no greater than 3 times uln (no greater than 5 times uln in case of hepatic metastases) renal * creatinine no greater than 2 times uln cardiovascular * no new york heart association class iii or iv heart disease other * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no uncontrolled infection * no other prior malignancy in past 5 years except adequately treated basal cell or squamous cell skin cancer or other adequately treated noninvasive carcinomas * no other concurrent severe underlying disease prior concurrent therapy: biologic therapy * no prior biologic, gene, or immunotherapy chemotherapy * no prior chemotherapy for nsclc except low dose cisplatin as radiosensitizer endocrine therapy * not specified radiotherapy * prior radiotherapy to less than 25% of bone marrow allowed surgery * not specified

Keywords: recurrent non-small cell lung cancer stage iv non-small cell lung cancer
pain reduction caused by the combined treatment of physiotherapy, oral gabapentin and oral ibuprofen arginine.

Conditions: Carpal Tunnel Syndrome

Summary: in the present investigation the pain reduction effects of a physiotherapy technique combined with gabapentin and ibuprofen arginine will be compared to those produced by an ibuprofen arginine (only) treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.

the present randomized clinical trial will perform a comparison of (group 1) the pain reduction effects produced by the application of a non invasive and non pharmacological median nerve neural mobilization (physiotherapy treatment) combined with a pharmaceutical oral gabapentin treatment versus (group 2) median nerve neural mobilization (physiotherapy treatment) combined with a pharmaceutical oral ibuprofen arginine treatment, to those effects produced by (group 3) ibuprofen arginine (only) treatment. additionally, effects over the functionality of the affected upper limb will be evaluated and compared. subjects will be invited to participate and randomly allocated to 2 different groups.

Eligibility criteria:
inclusion criteria: * participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings). * full understanding of written and spoken spanish (language). * participants must freely consent to participate. * the presence of positive phalen an tinel sings. * the presence of carpal tunnel syndrome signs and symptoms exclusion criteria: * the lack to meet inclusion criterions, the presence of cognitive impairment, tumors, cancer, recent (affected) upper limb surgery or trauma, pregnancy, kinesiophobia, deformities of the (affected) upper limb, recent skin injuries or infections (in the affected upper limb), autoimmune inflammatory conditions or flu type symptoms, allergy to gabapentin, allergy to ibuprofen arginine, and also: participants must not be (during the present investigation) under any type of pain reducing treatment (conservative, homeopathic, invasive or not invasive)
ct colonography as the initial diagnostic imaging tool for patients with suspected colorectal cancer

Conditions: Colorectal Cancer

Summary: this study aims to evaluate whether the use of computed tomography colonography (ctc) for patients with low to intermediate risk of suspected colorectal cancer decreases overall nhs costs and waiting times whilst increasing patient satisfaction compared to clinical practice with utilisation of optical colonoscopy.

given the recent change in the nice guidance for the cancer pathway referral for patients with suspected colorectal cancer (see ng12), there will be an increase in demand for optical colonoscopy. optical colonoscopy is technically difficult, resource intensive and associated with complications; therefore the increased use of ct colonography (ctc) should be considered as an alternative. the diagnostic efficacy of ctc, in comparison to optical colonoscopy, is well established and has been shown to be accurate for identifying malignancies and medium to large polyps (≥6mm) with a greater level of patient acceptability. the use of ctc as the first diagnostic imaging tool would identify those patients who would benefit from further investigation (colonoscopy or flexible sigmoidoscopy) to occur on the same day, as well as ruling out those who do not require further testing. this would then ensure that colonoscopy capacity can be prioritised appropriately to support the increase in demand due to the nice guidance changes.

Eligibility criteria:
inclusion criteria: * every adult patient over 40 years old, presenting with constipation or alternating change in bowel habits, with a differential diagnosis of suspected colorectal cancer. exclusion criteria: * patients presenting with anaemia; * patients presenting with diarrhoea only for more than 6 weeks; * patients presenting with rectal bleeding; * patients who have undergone a previous whole-colon examination in the past 6 months; * patients who have been referred for a whole-colon examination to follow up already diagnosed colorectal cancer; * patients lacking capacity to give consent or participate in the study; * patients already taking part in any clinical trial of an investigational medicinal product (ctimp); * prisoners * patients who are not fluent in english.
pharmacokinetics in adolescents

Conditions: Asthma

Summary: the purpose of this study is to study pharmacokinetics in adolescents.

an open, single centre, phase i study in male adolescents with asthma, aged 12 to 17 years, to assess pharmacokinetics of orally administered azd1981 tablets 100 mg twice daily for 61/2 days.

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures * a minimum of 6 months documented history of asthma * be a non-smoker or ex-smoker who has stopped smoking for \>6 months prior to visit 1 (pre-entry) exclusion criteria: * any clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the result of the study, or the patient's ability to participate * any clinically relevant abnormal findings in phys.examination, clinical chemistry, haematology, urinalysis, vital signs, or ecg at baseline which, in the opinion of the investigator, may put the patient at risk because of his participation in the study

Keywords: pharmacokinetics azd1981 asthma
evaluation of the gore® excluder® thoracoabdominal branch endoprosthesis in the treatment of the thoracoabdominal and pararenal aortic aneurysms (tambe)

Conditions: Thoracoabdominal Aneurysm

Summary: expanded access tothe gore® excluder® thoracoabdominal branch endoprosthesis is safe and effective in the treatment of thoracoabdominal and pararenal aneurysms.

gore will permit the use of the tambe device in a manner consistent with the approved cip provided that its use is needed to treat a serious, but non-life-threatening condition. in the requesting physician's opinion, there must be no acceptable alternative treatment option. patients are to be consented with an emergency / compassionate use icf template provided by gore upon request for this type of device use. sites will be required to fill out a packet justifying the rationale of use as well as their plan to conduct follow-up surveillance on the non-study subject. upon performance of the case, the site will immediately notify gore and provide supporting documentation to facilitate timely, compliant regulatory reporting.

Eligibility criteria:
• aortic aneurysm involving the visceral vessels requiring treatment defined as at least one of the following: fusiform aneurysm diameter ≥ 5 cm saccular aneurysm (no diameter requirement) rapid aneurysm growth (≥ 5 mm in one year) * an informed consent form signed by subject or legal representative * appropriate aortic anatomy to receive the tambe device d
transcriptomics signature of anti vaccinia memory b cells

Conditions: Healthy

Summary: analyse the transcriptomic signature of anti vaccinia memory b cells at a short time after vaccination as compared to the signature already established in long-lived memory b cells.


Eligibility criteria:
inclusion criteria: * healthy donors vaccinated against smallpox exclusion criteria: * none

Keywords: immunological memory
antibiotics versus placebo in the treatment of abscesses in the emergency department

Conditions: Abscess

Summary: the purpose of this study is to determine if there is a difference between an antibiotic, trimethoprim-sulfamethoxazole versus placebo in healing outcomes of soft tissue abscesses following incision and drainage.


Eligibility criteria:
inclusion criteria: * age 3 months to 17 years * single, localized soft tissue abscesses requiring incision and drainage with purulent material obtained * diameter of the abscess less than 5cm as measured by the treating physician exclusion criteria: * signs of systemic illness or ill-appearing, as determined by the treating physician * admission to the hospital following treatment in the emergency department * known sulfa allergy * immunocompromised patients * soft tissue abscesses involving the perineum (labia, scrotum, penis, perirectal) * previous antibiotic use (for any reason) in the past seven days * non-english speaking patients and families

Keywords: abscess outcomes antibiotics incision and drainage skin abscess
fat metabolites and gut hormones

Conditions: Overweight and Obesity; Type 2 Diabetes; Bariatric Surgery; Gut Hormones; Dietary Fat

Summary: to investigate the effects of different fat metabolites on gut hormone secretion in gastric bypass operated subjects and bmi-matched controls.

dietary triglycerides are hydrolyzed during digestion to two fatty acids and one 2-monoacyl glycerol. the study will investigate the effects of these different fat components on gut hormone secretion in gastric bypass operated patients and non-operated bmi-matched controls.

Eligibility criteria:
gastric bypass operated patients: inclusion criteria: * uncomplicated gastric bypass surgery performed minimum 12 months prior to study exclusion criteria: * type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery * pregnancy or breastfeeding * haemoglobin levels below 6,5 mm * gall bladder removal healthy control subjects: exclusion criteria: * bariatric surgery or complicated upper abdominal surgery * gall bladder removal * pregnancy or breastfeeding * haemoglobin levels below 6,5 mm * co-morbidities or medicine significantly affecting glucose metabolism or appetite regulation
bipap for cardiomyopathy with central sleep apnea

Conditions: Dilated Cardiomyopathy

Summary: we investigated whether treatment of central sleep apnea-hypopnea with bilevel positive airway pressure (bipap) in patients with idiopathic dilated cardiomyopathy (idcm) would improve lv function.


Eligibility criteria:
inclusion criteria: * idiopathic dilated cardiomyopathy exclusion criteria: * a history of alcohol abuse, diabetes mellitus, endocrine disorders, hypertension, obstructive sleep apnea syndrome, and chronic obstructive pulmonary disease
localized leiomyosarcoma biomarker protocol

Conditions: Leiomyosarcoma

Summary: * leiomyosarcoma (lms) is one of the more common soft tissue sarcomas (sts). * patients presenting with large, high-grade, localized lms are at significant risk of developing metastasis following curative surgery. * clinical trials of neoadjuvant or adjuvant anthracycline and ifosfamide have suggested that patients with localized sts who are at high-risk of metastasis may benefit from chemotherapy, but the magnitude of benefit in unselected patient population is relatively small. * currently, patient age, and tumor size and grade are used to assess risk of metastases and survival * studies evaluating tumor response by imaging and histopathology have not established correlation between tumor characteristics as biomarkers for risk of metastasis or sarcoma recurrence. * circulating tumor dna (ctdna) is present in blood of patients with advanced/metastatic lms and may serve as biomarker of tumor response to chemotherapy. blood samples will be collected prior to, during and after chemotherapy and analyzed for ctdna and for mutations in genes that are associated with increased risk of developing sarcoma. tumor tissue will be collected and analyzed for changes in genes. digital images of the sarcoma from ct or mri scans obtained during treatment will be obtained for advanced radiomic analysis. patients will be followed for 2 years after study entry for signs of sarcoma recurrence. * a biomarker of tumor response and patient survival benefit from chemotherapy early in the course of chemotherapy would be of significant impact in treatment planning.


Eligibility criteria:
inclusion criteria: * patients with localized leiomyosarcoma (lms) of extremity, body wall or retroperitoneum * grade 2 or 3, or high-grade lms * tumor size \>5 cm in greatest dimension * primary tumor amenable to complete resection * there is no age requirement * participant agrees to receive neoadjuvant doxorubicin and ifosfamide combination chemotherapy * if pre-operative radiation is administered, it must be administered after chemotherapy. post-operative radiation may be administered * archival tumor tissue (either frozen sample, tissue block containing tumor, or minimum of 4 unstained slides and 1 h\&e stained slide) from diagnostic or pre-treatment biopsy available for study research

Keywords: ctdna radiomics biomarker